OncBioMune Pharmaceuticals, Inc. announced that it expects to receive $0.134375 million in funding from LG Capital Funding, LLC
January 17, 2019
Share
OncBioMune Pharmaceuticals, Inc. (OTCPK:OBMP) announced that it has entered into a securities purchase agreement with LG Capital Funding, LLC for the private placement of a convertible redeemable note of $146,875 issued at a discount for gross proceeds of $134,375 on January 18, 2019. The note bear an interest of 5% per annum and will mature on January 18, 2020. The holder may convert all or a portion of the outstanding principal of the note into common shares at a fixed conversion price of $0.02 per share for the first six months post which the conversion price shall be equal to 60% of the lowest trading price of the shares during the 20 prior trading days. The company must pay the principal at a cash redemption premium of 115%, in addition to accrued interest if the company prepays the note within 150 days of its issuance; if such prepayment is made from the 151st day to the 180th day after issuance, then such redemption premium is 120%, in addition to accrued interest. There is no further right of prepayment after the 180th day following the issuance of the note.
Theralink Technologies, Inc. is a proteomics-based, precision medicine company. The Company's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDT, the Theralink Assay for Breast Cancer, is utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer. The Company is also working on a second assay for advanced breast cancer that is planned to be pan-tumor for solid tumors across multiple tumor types, such as ovarian, endometrial, liver, head and neck, colorectal, lung, and prostate, among others. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both Food and Drug Administration approved and investigational drug treatments.
THERALINK TECHNOLOGIES, INC. 
